CompletedPHASE1, PHASE2NCT04398433

INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)

Studying Recurrent respiratory papillomatosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Inovio Pharmaceuticals
Principal Investigator
Jeffrey Skolnik, MD
Inovio Pharmaceuticals
Intervention
INO-3107(drug)
Enrollment
32 target
Eligibility
18 years · All sexes
Timeline
20202022

Study locations (11)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04398433 on ClinicalTrials.gov

Other trials for Recurrent respiratory papillomatosis

Additional recruiting or active studies for the same condition.

See all trials for Recurrent respiratory papillomatosis

← Back to all trials